Episode 219: ASCO GU 2023: Neeraj Agarwal, MD...

summaryThis episode explores the latest advances in circulating tumor DNA (ctDNA) and urinary tumor DNA (utDNA) in bladder cancer management. Experts discuss how these biomarkers are transforming perioperative decision-making, prognosis, and personalized treatment strategies. 

This detailed discussion covers the latest phase three trial results in kidney cancer, focusing on LITESPARK 011: Belzutifan plus Lenvatnib versus Cabozantinib. Brian, Tom and Bob Motzer analyze efficacy, safety, and implications for treatment sequencing. 

JAMA Deputy Editor and JAMA Oncology Editor Mary (Nora) L. Disis, MD, speaks with Kimmie Ng, MD, MPH, chair of the meeting's Scientific Program Committee and associate chief of the Division of Gastrointestinal Oncology at Dana-Farber Cancer Institute.

Rela ...

Combined Otolaryngology Spring Meetings Chair Patrick Ha, MD, and Co-Chairs Nicole C. Schmitt, MD, and Sidharth V. Puram, MD, PhD, share late-breaking research from the annual Combined Otolaryngology Spring Meetings in an interview hosted by JAMA Otolaryngology Web Editor Paul C. ...  Show more

Dr. Lauren Kim discusses results from the 20-year follow-up of the International Early Lung Cancer Action Program with Dr. Claudia Henschke, Dr. Rowena Yip, and Dr. David Yankelevitz. A 20-year Follow-up of the International Early Lung Cancer Action Program (I-ELCAP). Henschke an ...  Show more

Dr. Refky Nicola discusses the Society of Radiologists in Ultrasound Consensus Conference recommendations on management of incidentally detected gallbladder polyps with Dr. Paul Sidhu. Management of Incidentally Detected Gallbladder Polyps: Society of Radiologists in Ultrasound C ...  Show more